MedTrace Logo

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

NCT00663026 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2013-11-15

Study results available
· View outcomes & findings →

Summary

The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.

Conditions

  • Alzheimer Disease

Interventions

DRUG

bapineuzumab

5 mg bapineuzumab subcutaneous injection once per week for 6 months

DRUG

bapineuzumab

10 mg bapineuzumab subcutaneous injection once per week for 6 months

DRUG

placebo

Placebo subcutaneous injection once per week for 6 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663026 on ClinicalTrials.gov